Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cost of Revenue (2016)

Viridian Therapeutics, Inc.\DE (VRDN) has 3 years of Cost of Revenue data on record, last reported at -$187000.0 in Q4 2016.

  • For Q4 2016, Cost of Revenue fell 127.99% year-over-year to -$187000.0; the TTM value through Dec 2016 reached $1.7 million, down 29.19%, while the annual FY2016 figure was $1.7 million, 32.48% down from the prior year.
  • Cost of Revenue reached -$187000.0 in Q4 2016 per VRDN's latest filing, down from $599000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $3.1 million in Q4 2014 and bottomed at -$1.0 million in Q3 2014.
  • Average Cost of Revenue over 3 years is $515396.2, with a median of $543500.0 recorded in 2015.
  • Peak YoY movement for Cost of Revenue: soared 927.27% in 2015, then plummeted 127.99% in 2016.
  • A 3-year view of Cost of Revenue shows it stood at $3.1 million in 2014, then plummeted by 78.21% to $668000.0 in 2015, then plummeted by 127.99% to -$187000.0 in 2016.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were -$187000.0 in Q4 2016, $599000.0 in Q3 2016, and $747000.0 in Q2 2016.